Proactive Investors - Run By Investors For Investors

Mallinckrodt rings up higher 3Q earnings and revenue; raises EPS guidance

Company's performance buoyed by strong consumer demand for its pharmaceutical products
medical pills in production
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies

Global specialty pharmaceutical company Mallinckrodt PLC (NYSE:MNK) reported on Tuesday higher earnings and revenue for the third quarter while raising its earnings guidance for the full year, giving its shares a modest boost during the trading session.

The company said revenue for the quarter hit $640 million, topping the consensus of $635.89 million. EPS reached $2.10, above the year-ago level of $1.82 and the consensus of $1.80.

Adjusted net income over the first nine months was $439.6 million, compared with $418 million. Adjusted diluted earnings per share were $5.16 compared with $4.19.

The company raised its full-year EPS guidance to $7.00 to $7.20, compared with the previous $6.50 to $6.90.

"Mallinckrodt performed well in the third quarter driven by strong customer demand for our hospital products and effective expense management," said Mark Trudeau, the president and CEO of Mallinckrodt.

Shares of the company jumped as high as 10.45% to a session peak of $30 before trimming its gains.

READ: Shares of Mallinckrodt rally after 2Q profit and revenue beat

The company said its third-quarter debt was reduced by $170.6 million and that total debt reduction was at $630.7 million since the end of the first quarter.

Trudeau said "tight expense control also helped us support increased R&D investments in our innovative pipeline" and the performance of the company enabled them to raise the guidance on EPS for the year.

"We continue to be pleased with the performance trajectory of H.P. Acthar Gel and we also look forward to a number of important clinical data and regulatory updates across the portfolio in coming quarters. Finally, we continue to make strong progress against our objective of reducing debt," he said.

Acthar Gel is a purified preparation of adrenocorticotropic hormone (ACTH) designed to provide extended release of the ACTH following injection. ACTH stimulates the adrenal cortex gland to secrete cortisol, corticosterone, and aldosterone andi s used to treat multiple sclerosis in adults and systemic lupus in kidneys.

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies.

The company is based in Staines-Upon-Thames, United Kingdom.

Reporting by Rene Pastor, contactable on [email protected]

View full MNK profile View Profile

Mallinckrodt PLC Timeline

Related Articles

Polish pizza
March 27 2019
In 2018, DP Poland’s system sales rose by 24% to 72mln Polish zloty (PLN) from PLN 58mln in 2017, despite a tough second half to the year as aggregators took a bite from its business
US bills and cannabis plant
February 27 2019
CEO Mike Withrow has built AREV into what is now a cannabis and hops company that owns a series of promising businesses
true leaf pet product
March 29 2019
The company says both the cannabis and pet industries represent high-growth industries
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use